Clinical Trials Browser

Phase 3 × Neoplasms, Plasma Cell × Bortezomib × Clear all

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01208766 2026-01-06

HO95

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01191060 2019-04-18

IFM/DFCI2009

Phase 3 Completed

Disease Progression, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00111748 2015-10-06

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00093028 2010-07-02

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell